Facts and figures

products icon

27.7 million patients use our diabetes products

products icon

Our products are marketed in 170 countries

affiliates icon

We have affiliates in 79 countries


STRATEGIC FOCUS AREAS
 

Share of sales circle
Share of sales

PERFORMANCE
 

Annual sale 2017


111,696 million Danish kroner 

Q3 2018


27,762 million Danish kroner

Third-quarter results 2018

 

Sales by region
Q3 2018


North America Operations

14,103 million Danish kroner


USA: 13,476 million Danish kroner

Canada: 627 million Danish kroner

 

International Operations

13,659 million Danish kroner


Region Europe: 5,392 million Danish kroner

Region AAMEO: 3,067 million Danish kroner

Region China: 2,793 million Danish kroner

Region Japan & Korea: 1,446 million Danish kroner

Region Latin America: 961 million Danish kroner

 

Sales by business segment
Q3 2018


Diabetes and obesity care total

23,366 million Danish kroner

 

Biopharmaceuticals total

4,396 million Danish kroner

 


R&D AT A GLANCE
 

research icon

We invest 12,5% of sales in R&D
 

employee icon

19% of our global workforce works within R&D

research icon

We have R&D centres in China, Denmark, India and the US


We have five main product areas


Diabetes
Obesity
Haemophilia
Growth disorders
Hormone replacement therapy

Product overview
 

Our devices

Diabetes pens and needles
Growth hormone pens
 


OUR PEOPLE

Number of employees

Approximately 43,200 full time employees (FTEs) September 2018.


Business area distribution

19% within research and development

32% in production and production administration

37% in international sales and marketing

12% in administration
 

#

Affiliate distribution (FTEs as of September 2018)

Approximately 40% of employees are located in Denmark (17,295 FTEs) and 60% in the rest of the world:

Africa, Asia, Middle East & Oceania: 7,131

China & Taiwan: 4,586

Denmark: 17,295

Europe (excl. HQ): 4,518

Japan (1,137) & Korea: 1,279

Latin America: 1,961

North America (US 6,093 & Canada 298): 6,391

(includes Novo Nordisk and NNE employees)

 


PRODUCTION AT A GLANCE
 

affiliates icon

We supply nearly half the world's insulin

 

Clean energy icon

By 2020 all our production will run on 100% renewable power

research icon

We have production sites in Brazil, China, Denmark, France and the US


HEADQUARTERS

We are located in Denmark

Novo Nordisk A/S
Novo Allé 1
2880 Bagsværd
Denmark
CVR nr. 24 25 67 90

Contact us